GO:0004082 bisphosphoglycerate mutase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004082 describes the enzymatic activity that converts 3-phospho-D-glyceroyl phosphate to 2,3-bisphospho-D-glycerate, a key reaction in erythrocyte metabolism.
• The BPGM gene encodes the enzyme responsible for this activity in humans, and its product is essential for regulating hemoglobin oxygen affinity.
• Alterations in bisphosphoglycerate mutase activity have been observed in breast, lung, colon, and liver carcinomas, suggesting a role in cancer metabolism.
• The enzyme also exhibits phosphatase activity toward 2-phosphoglycolate, linking it to glycolate detoxification.
• In chronic kidney disease, sphingosine 1-phosphate signaling reprograms erythrocyte metabolism, affecting 2,3-BPG levels and oxygen delivery.
• Research on this activity employs knockout, point-mutation, and overexpression models to dissect its metabolic and disease-related functions.
Description
Bisphosphoglycerate mutase activity (GO:0004082) is a molecular function defined as the catalysis of the reaction: 3-phospho-D-glyceroyl phosphate = 2,3-bisphospho-D-glycerate. This enzymatic step is central to the Rapoport-Luebering shunt, a bypass of the glycolytic pathway that generates 2,3-bisphosphoglycerate (2,3-BPG), a critical allosteric regulator of hemoglobin oxygen affinity. The activity is encoded by the BPGM gene in humans and is distinct from the glycolytic enzyme phosphoglycerate mutase (PGAM), although both belong to the phosphoglycerate mutase family. Researchers study GO:0004082 to understand erythrocyte metabolism, oxygen transport, and metabolic reprogramming in diseases such as cancer and chronic kidney disease. The enzyme's dual mutase and phosphatase activities further expand its biological significance, particularly in the context of 2-phosphoglycolate detoxification. Given its role in red blood cell physiology and emerging links to tumor metabolism, bisphosphoglycerate mutase activity represents a promising target for both basic and translational research.
bisphosphoglycerate mutase activity At A Glance
| GO ID | GO:0004082 |
|---|---|
| GO term | bisphosphoglycerate mutase activity |
| Ontology | molecular_function |
| Synonym | 2,3-bisphosphoglycerate mutase activity; 2,3-bisphosphoglycerate synthase activity; 2,3-diphosphoglycerate mutase activity; BPGM activity; DPGM |
| Major function | Catalysis of the reaction: 3-phospho-D-glyceroyl phosphate = 2,3-bisphospho-D-glycerate |
| Reaction direction | Reversible interconversion |
| Substrate | 3-phospho-D-glyceroyl phosphate |
| Product | 2,3-bisphospho-D-glycerate |
| Cofactor | Not required (phosphoglycerate mutase family, cofactor-independent) |
| Cellular location | Cytoplasm |
| Associated gene | BPGM |
What Is GO:0004082?
Bisphosphoglycerate mutase activity (GO:0004082) is the catalytic activity that converts 3-phospho-D-glyceroyl phosphate into 2,3-bisphospho-D-glycerate. This reaction is a mutase-type rearrangement, where the phosphate group is transferred within the molecule to form the bisphosphorylated product. The activity is synonymous with 2,3-bisphosphoglycerate mutase, 2,3-bisphosphoglycerate synthase, and 2,3-diphosphoglycerate mutase, among others. It is a molecular function that resides in the cytoplasm and is particularly abundant in erythrocytes, where the product 2,3-BPG modulates hemoglobin's affinity for oxygen.
Why Is bisphosphoglycerate mutase activity Important in Cell Biology?
Bisphosphoglycerate mutase activity is essential for red blood cell physiology because its product, 2,3-bisphosphoglycerate, binds to hemoglobin and reduces its oxygen affinity, facilitating oxygen release to tissues. This function is critical for adapting to hypoxia and maintaining oxygen homeostasis. Beyond erythrocytes, the activity has been implicated in cancer metabolism, where altered expression and activity of the enzyme are observed in breast, lung, colon, and liver carcinomas. Additionally, the enzyme's phosphatase activity toward 2-phosphoglycolate connects it to cellular detoxification pathways. In chronic kidney disease, metabolic reprogramming of erythrocytes by sphingosine 1-phosphate affects 2,3-BPG levels, highlighting the clinical relevance of this activity. Thus, understanding GO:0004082 offers insights into oxygen transport, metabolic disorders, and potential therapeutic targets.
• Regulates hemoglobin oxygen affinity via 2,3-BPG production.
• Involved in the Rapoport-Luebering shunt, a glycolytic bypass.
• Altered activity in breast, lung, colon, and liver cancers.
• Exhibits phosphatase activity toward 2-phosphoglycolate, aiding detoxification.
• Dysregulated in chronic kidney disease through S1P signaling.
• Potential therapeutic target in hepatocellular carcinoma metabolism.
• Congenital erythrocytosis can result from mutations affecting this pathway.
• Provides a model for studying enzyme evolution in the phosphoglycerate mutase family.
• Relevant to hypoxia adaptation and oxygen delivery in tissues.
• Offers a tool for metabolic engineering and drug discovery.
Molecular Mechanism of bisphosphoglycerate mutase activity
Substrate Binding and Catalysis
In simple terms: The enzyme grabs a molecule called 3-phospho-D-glyceroyl phosphate and rearranges it to make 2,3-bisphospho-D-glycerate.
Bisphosphoglycerate mutase catalyzes the reversible conversion of 3-phospho-D-glyceroyl phosphate to 2,3-bisphospho-D-glycerate. The reaction proceeds through a phosphoenzyme intermediate, where the enzyme temporarily transfers a phosphate group to itself before donating it to the substrate. This mechanism is characteristic of the cofactor-independent phosphoglycerate mutase family, which includes BPGM. The active site contains conserved residues that facilitate the phosphoryl transfer, and the reaction is essential for maintaining 2,3-BPG levels in erythrocytes.
Phosphatase Activity and 2-Phosphoglycolate
In simple terms: The enzyme can also act as a phosphatase, removing phosphate groups from certain molecules like 2-phosphoglycolate.
Beyond its mutase activity, bisphosphoglycerate mutase exhibits phosphatase activity toward 2-phosphoglycolate, converting it to glycolate. This dual functionality suggests a role in detoxifying 2-phosphoglycolate, a byproduct of RuBisCO oxygenation in plants and a potential toxic metabolite in other organisms. Structural studies have revealed that 2-phosphoglycolate binds to the active site and activates the phosphatase activity, providing molecular insight into substrate promiscuity. This activity may be particularly relevant in conditions of oxidative stress or metabolic imbalance.
Regulation by Phosphorylation
In simple terms: Adding a phosphate tag to the enzyme can turn its activity on or off.
In Arabidopsis thaliana, the activity of 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 2 requires phosphorylation at serine 82. Although this plant enzyme is distinct from human BPGM, the finding highlights that phosphorylation can regulate phosphoglycerate mutase family members. In humans, BPGM activity may be modulated by post-translational modifications, though specific phosphorylation sites remain to be fully characterized. This regulatory layer allows fine-tuning of 2,3-BPG production in response to metabolic demands.
Role in Erythrocyte Metabolism
In simple terms: In red blood cells, this enzyme helps control how much oxygen hemoglobin releases to tissues.
The Rapoport-Luebering shunt, which includes bisphosphoglycerate mutase, diverts glycolytic intermediates to produce 2,3-BPG. By generating 2,3-BPG, the enzyme reduces hemoglobin's oxygen affinity, promoting oxygen unloading in tissues. This shunt is particularly active in erythrocytes, where 2,3-BPG concentrations are high. Dysregulation of this pathway can lead to congenital erythrocytosis or affect oxygen delivery in chronic diseases.
Metabolic Reprogramming in Disease
In simple terms: In cancer and kidney disease, the enzyme's activity can change, affecting cell metabolism.
Altered bisphosphoglycerate mutase activity has been observed in breast, lung, colon, and liver carcinomas, suggesting a role in tumor metabolic reprogramming. In chronic kidney disease, sphingosine 1-phosphate signaling reprograms erythrocyte metabolism, impacting 2,3-BPG levels and oxygen delivery. These findings indicate that the enzyme is not only a housekeeping metabolic protein but also a responsive node in disease-associated metabolic networks.
Key Genes Involved in GO:0004082 bisphosphoglycerate mutase activity
The following genes and proteins are directly or indirectly associated with bisphosphoglycerate mutase activity (GO:0004082) and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BPGM | Encodes bisphosphoglycerate mutase, catalyzing 2,3-BPG synthesis | Primary gene for GO:0004082; mutations linked to erythrocytosis |
| PGAM1 | Phosphoglycerate mutase 1, glycolytic enzyme | Related family member; often co-expressed and studied in cancer |
| PGAM2 | Phosphoglycerate mutase 2, muscle isoform | Distinct from BPGM but shares evolutionary origin |
| PGK1 | Phosphoglycerate kinase 1, produces 3-phosphoglyceroyl phosphate | Upstream of BPGM in glycolysis; provides substrate |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Glycolytic enzyme generating 1,3-BPG, precursor to BPGM substrate |
| EPO | Erythropoietin | Regulates red blood cell production; indirectly affects BPGM expression |
| HIF1A | Hypoxia-inducible factor 1-alpha | Regulates oxygen homeostasis; may influence BPGM expression |
| S1PR1 | Sphingosine-1-phosphate receptor 1 | Mediates S1P signaling in CKD, affecting erythrocyte metabolism |
| SLC2A1 | GLUT1 glucose transporter | Facilitates glucose uptake for glycolysis in erythrocytes |
| PKLR | Pyruvate kinase L/R | Glycolytic enzyme; mutations cause hemolytic anemia, affecting BPGM pathway |
| G6PD | Glucose-6-phosphate dehydrogenase | Protects erythrocytes from oxidative stress; interacts with metabolic pathways |
| ALDOA | Aldolase A | Glycolytic enzyme; potential metabolic context |
| ENO1 | Enolase 1 | Glycolytic enzyme; studied alongside BPGM in cancer |
| TPI1 | Triosephosphate isomerase 1 | Glycolytic enzyme; deficiency affects red cell metabolism |
| LDHA | Lactate dehydrogenase A | Anaerobic glycolysis marker; co-regulated with BPGM in tumors |
| SLC4A1 | Band 3 anion exchanger | Erythrocyte membrane protein; interacts with metabolic enzymes |
| AHSP | Alpha-hemoglobin stabilizing protein | Chaperone for hemoglobin; indirectly linked to 2,3-BPG effects |
How Is bisphosphoglycerate mutase activity Regulated?
Bisphosphoglycerate mutase activity is regulated at multiple levels. In erythrocytes, the Rapoport-Luebering shunt is controlled by the availability of glycolytic intermediates and the activity of upstream enzymes such as phosphoglycerate kinase. Hypoxia and erythropoietin signaling can influence red blood cell metabolism, indirectly affecting 2,3-BPG levels. In chronic kidney disease, sphingosine 1-phosphate signaling reprograms erythrocyte metabolism, leading to altered 2,3-BPG production. Additionally, phosphorylation of phosphoglycerate mutase family members, as shown for Arabidopsis thaliana iPGAM2, suggests that post-translational modifications may regulate activity. In cancer, oncogenic signaling pathways such as HIF-1α and mTOR may modulate glycolytic flux, impacting BPGM function.
bisphosphoglycerate mutase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BPGM | Congenital erythrocytosis | Knockout mouse or patient-derived iPSCs |
| BPGM | Cancer metabolism (breast, lung, colon, liver) | Cancer cell lines with BPGM overexpression or knockout |
| BPGM | Chronic kidney disease | CKD mouse models treated with S1P modulators |
| PGAM1 | Cancer glycolysis | PGAM1 knockout cancer cells |
| EPO | Erythrocytosis | EPO-overexpressing transgenic mice |
Congenital Erythrocytosis
Mutations in BPGM or other genes affecting the Rapoport-Luebering shunt can lead to congenital erythrocytosis, characterized by increased red blood cell mass and elevated hemoglobin. Dysregulation of 2,3-BPG levels alters oxygen affinity, prompting compensatory erythropoiesis. Genetic testing for BPGM mutations is part of the diagnostic workup for unexplained erythrocytosis.
Cancer Metabolism
Altered bisphosphoglycerate mutase activity has been observed in breast, lung, colon, and liver carcinomas. In hepatocellular carcinoma, metabolic reprogramming supports tumor growth, and targeting glycolytic enzymes including BPGM is being explored. The enzyme's contribution to 2,3-BPG production may influence tumor hypoxia and angiogenesis.
Chronic Kidney Disease
In chronic kidney disease, sphingosine 1-phosphate signaling reprograms erythrocyte metabolism, affecting 2,3-BPG levels and oxygen delivery. This metabolic adaptation may contribute to anemia and tissue hypoxia in CKD patients. Therapies targeting S1P signaling could modulate BPGM activity and improve oxygen transport.
Neurodegeneration and Other Disorders
While direct links between BPGM and neurodegeneration are not well established, metabolic dysregulation is a common feature of neurodegenerative diseases. The enzyme's role in 2-phosphoglycolate detoxification suggests potential relevance in oxidative stress-related conditions. Further research is needed to clarify any causal relationships.
From bisphosphoglycerate mutase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of BPGM loss on erythrocyte 2,3-BPG levels? | BPGM knockout cell line (e.g., K562) or mouse |
| Does a specific BPGM mutation alter enzyme activity? | Point-mutation knock-in via CRISPR in HEK293 cells |
| How does BPGM overexpression affect cancer cell metabolism? | Cancer cell lines with doxycycline-inducible BPGM overexpression |
| What is the subcellular localization of BPGM? | Tagged knock-in (e.g., GFP-BPGM) in erythroid cells |
| Which proteins interact with BPGM? | Knock-in of epitope-tagged BPGM followed by immunoprecipitation |
| Can BPGM compensate for PGAM deficiency? | Double knockout of PGAM and BPGM in cell lines |
How to Study the bisphosphoglycerate mutase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Catalytic conversion of substrate to product | Kinetic characterization of BPGM mutants |
| Metabolomics (LC-MS) | Levels of 2,3-BPG and glycolytic intermediates | Assessing metabolic reprogramming in cancer |
| CRISPR knockout screen | Gene essentiality and pathway interactions | Identifying regulators of 2,3-BPG production |
| Western blot | Protein expression levels | Validating BPGM overexpression or knockout |
| Immunoprecipitation | Protein-protein interactions | Identifying BPGM binding partners |
| X-ray crystallography | Three-dimensional structure | Understanding substrate binding and catalysis |
| RNA-seq | Transcriptional changes | Evaluating global effects of BPGM perturbation |
| Ribo-seq | Translation efficiency | Measuring changes in protein synthesis upon BPGM modulation |
Enzymatic Activity Assays
Bisphosphoglycerate mutase activity can be measured spectrophotometrically by coupling the reaction to NADH oxidation or by monitoring the formation of 2,3-BPG using ion-exchange chromatography. These assays are used to quantify enzyme kinetics and screen for inhibitors.
Metabolomics and 2,3-BPG Quantification
Mass spectrometry-based metabolomics allows direct quantification of 2,3-BPG and other glycolytic intermediates in cell lysates or tissues. This approach is essential for assessing the impact of genetic perturbations on the Rapoport-Luebering shunt.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate 2,3-BPG levels or BPGM activity, revealing synthetic lethal interactions and regulatory networks. Such screens are particularly useful in cancer metabolism research.
Structural Biology
X-ray crystallography and cryo-EM have been used to solve the structure of BPGM and its complexes with substrates or inhibitors. These studies provide atomic-level insights into the catalytic mechanism and substrate specificity.
How CRISPR Can Be Used to Study GO:0004082 bisphosphoglycerate mutase activity
Knockout
CRISPR-Cas9 knockout of BPGM in erythroid cell lines or cancer cells abolishes bisphosphoglycerate mutase activity, leading to reduced 2,3-BPG levels and altered oxygen affinity. Knockout models are used to study the metabolic consequences and compensatory pathways.
Point Mutation
Introducing specific point mutations in BPGM via CRISPR base editing or homology-directed repair allows researchers to dissect the catalytic residues and regulatory phosphorylation sites. Such models help distinguish between mutase and phosphatase activities.
Knock-in
Knock-in of tagged BPGM (e.g., FLAG or GFP) enables localization, interaction, and degradation studies. Conditional knock-in alleles can be used to express mutant BPGM in a tissue-specific manner, mimicking human mutations associated with erythrocytosis.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of BPGM increases 2,3-BPG production, which can be used to study its effects on hemoglobin oxygen affinity and cancer cell proliferation. Overexpression models are valuable for drug screening.
How EDITGENE Supports bisphosphoglycerate mutase activity Research
Researchers studying bisphosphoglycerate mutase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes associated with GO:0004082.
Contact EDITGENE today to design your custom CRISPR model for bisphosphoglycerate mutase activity research.
Frequently Asked Questions About bisphosphoglycerate mutase activity
What is bisphosphoglycerate mutase activity?
Bisphosphoglycerate mutase activity (GO:0004082) is the enzymatic catalysis of the reaction converting 3-phospho-D-glyceroyl phosphate to 2,3-bisphospho-D-glycerate, a key step in erythrocyte metabolism.
What genes are involved in bisphosphoglycerate mutase activity?
The primary gene is BPGM, which encodes the enzyme. Other related genes include PGAM1, PGAM2, and glycolytic enzymes like PGK1 and GAPDH.
What is the function of BPGM?
BPGM produces 2,3-bisphosphoglycerate, which regulates hemoglobin oxygen affinity and facilitates oxygen release to tissues.
How is bisphosphoglycerate mutase activity measured?
It can be measured using enzyme activity assays that monitor substrate conversion or 2,3-BPG formation, often coupled with spectrophotometry or mass spectrometry.
Is bisphosphoglycerate mutase activity involved in cancer?
Yes, altered activity has been observed in breast, lung, colon, and liver carcinomas, suggesting a role in tumor metabolism.
What diseases are associated with BPGM mutations?
Mutations in BPGM can cause congenital erythrocytosis, characterized by increased red blood cell mass.
Can bisphosphoglycerate mutase act as a phosphatase?
Yes, it exhibits phosphatase activity toward 2-phosphoglycolate, converting it to glycolate, which may aid detoxification.
How is bisphosphoglycerate mutase activity regulated?
It is regulated by substrate availability, post-translational modifications such as phosphorylation, and signaling pathways like S1P in chronic kidney disease.
What model systems are used to study bisphosphoglycerate mutase activity?
Common models include BPGM knockout cell lines, point-mutation knock-ins, and overexpression systems in erythroid or cancer cells.
Why is bisphosphoglycerate mutase activity important for oxygen transport?
By generating 2,3-BPG, it reduces hemoglobin's oxygen affinity, promoting oxygen delivery to tissues, especially under hypoxic conditions.
Conclusion
Bisphosphoglycerate mutase activity (GO:0004082) is a fundamental enzymatic function in erythrocyte metabolism and oxygen homeostasis. Its product, 2,3-BPG, is a critical regulator of hemoglobin oxygen affinity, and alterations in this activity are linked to congenital erythrocytosis, cancer metabolism, and chronic kidney disease. The enzyme's dual mutase and phosphatase activities further expand its biological roles. Continued research using CRISPR-based models will unravel the precise mechanisms and therapeutic potential of targeting this activity. EDITGENE's services support these efforts by providing custom-engineered cell models for functional studies.
References
- 1. Du D et al.. 2022. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.. Acta Pharm Sin B 12(2):558-580 PMID: 35256934
- 2. Aljahdali AS et al.. 2022. Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase.. Acta Crystallogr D Struct Biol 78(Pt 4):472-482 PMID: 35362470
- 3. Mallik N et al.. 2021. Congenital erythrocytosis.. Eur J Haematol 107(1):29-37 PMID: 33840141
- 4. Fothergill-Gilmore LA et al.. 1989. The phosphoglycerate mutases.. Adv Enzymol Relat Areas Mol Biol 62:227-313 PMID: 2543188
- 5. Duminil P et al.. 2021. Arabidopsis thaliana 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 2 activity requires serine 82 phosphorylation.. Plant J 107(5):1478-1489 PMID: 34174129
- 6. Durany N et al.. 2000. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.. Br J Cancer 82(1):20-7 PMID: 10638961
- 7. Durany N et al.. 1997. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.. Br J Cancer 75(7):969-77 PMID: 9083331
- 8. Xie T et al.. 2020. Erythrocyte Metabolic Reprogramming by Sphingosine 1-Phosphate in Chronic Kidney Disease and Therapies.. Circ Res 127(3):360-375 PMID: 32284030
